Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patients with active peripheral spondyloarthritis (pSpA)

Next Previous
Search
Trial Profile

A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patients with active peripheral spondyloarthritis (pSpA)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Anterior uveitis; Arthritis; Sacroiliitis; Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CAIN457X12301
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 08 Mar 2024 This trial has been discontinued in Italy (End Date: 23 August 2022) according to European Clinical Trials Database record.
    • 05 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 18 Sep 2022 This trial has been discontinued in Spain (End Date: 23 August 2022) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top